JAZZ

Jazz Pharmaceuticals plc

Fundamental data last updated:November 18, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

IE

Next Earnings Date

02/23/2027

Business Summary

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company has licensing and collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., and Werewolf Therapeutics, Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

 


VALUATION

P/E

67.14

Market Cap ($M USD)

$15.43B

Forward P/E

16.04

PEG

0.82

PRICE TO SALES

3.27

PRICE TO BOOK

3.71

EV / EBITDA

16.28

5-Year Average P/E

Free Cash Flow Yield

10.19%

DCF Value

$379.85

Graham Number

$68.12

Price to FCF

9.81

EV to FCF

12.10

Earnings Yield

1.32%

FCF Yield

10.19%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$3.18

Next Year EPS Growth Estimate

$14.98

Next Year Revenue Growth Estimate

$4.80B

Return on Equity (ROE)

4.62%

FREE CASH FLOW

Operating Margin

20.30%

Debt-to-Equity

1.35

Piotroski F-Score

7

Altman Z-Score

1.97

Return on Invested Capital (ROIC)

7.24%

Current Ratio

1.82

Quick Ratio

1.64

Net Debt to EBITDA

3.09

Interest Coverage

5.01

Gross Profit margin

88.17%

FCF PER SHARE

$24.31

REVENUE PER SHARE

$72.92

Gainseekers Quantitative Analysis

Summary

The market appears to be significantly undervaluing Jazz Pharmaceuticals. With a DCF value more than double the recent pricing, the stock seems poised for a potential upside. The Forward P/E of 6.78 suggests a stark contrast to its current P/E, indicating expectations of explosive earnings growth. However, the Altman Z-score of 1.84 raises concerns about financial stability, hinting at potential distress. The minuscule earnings yield further underscores the need for caution, despite the enticing valuation gap.

AI Exposure / Tech Reliance

Operating in the biotechnology sector, Jazz Pharmaceuticals is well-positioned to leverage AI advancements for drug discovery and personalized medicine. The industry's inherent reliance on cutting-edge technology provides a robust platform for adaptation. As AI continues to revolutionize healthcare, Jazz's strategic positioning could enhance its competitive edge.

The Bull Case

For the discerning GARP investor, Jazz Pharmaceuticals offers compelling reasons to buy. The robust ROIC of 5.14% and a healthy FCF yield suggest efficient capital allocation and strong cash generation. With a Piotroski F-Score of 6, the company demonstrates solid financial health. Its impressive operating margin of 11.13% indicates strong pricing power, making it an attractive proposition for value seekers.

The Bear Case

Despite its strengths, Jazz Pharmaceuticals faces notable risks. The stock's proximity to its 52-week high suggests potential overextension, raising caution for technical traders. The EV to EBITDA ratio of 44.86 signals a high valuation, which could deter conservative investors. Additionally, the net debt to EBITDA ratio of 9.03 highlights significant leverage, posing a risk in volatile market conditions.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$295.43

Institutional Ownership %

1-Year Beta

0.32

Insider Buying % (6 Mo)

Distance to 52-Week High

10.82%

Distance to 52-Week Low

43.19%

EARNINGS SURPRISE %

3.72%

50-DAY SMA

$229.35

200-DAY SMA

$219.26

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.